MUMBAI – Mylan NV President Rajiv Malik is in a sweet spot. The $6.8 billion Pittsburgh-headquartered generics drug maker is nearing windfall gains arising from a few hard-pursued programs. For one, the Indian government gave the green light to its $1.6 billion acquisition of Agila Specialties Pvt. Ltd. after looming doubts it would be approved.
Once integrated, Mylan hopes to gain a significant lead in the global injectables market via Agila’s pipeline of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?